Ironwood Pharmaceuticals Inc (IRWD)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Ironwood Pharmaceuticals Inc (IRWD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012204
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:71
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Ironwood Pharmaceuticals Inc (Ironwood) is a commercial biotechnology company that discovers, develops and commercializes medicines for gastrointestinal (GI) disorders. The company’s marketed products consist of Linzess (linaclotide), an oral capsule for the treatment of irritable bowel syndrome with constipation or chronic idiopathic constipation in adult men and women; and Zurampic (lesinurad) for the treatment of hyperuricemia associated with gout. Ironwood also evaluates linaclotide in other indications, new formulations and in combination with other products in various GI conditions. Its pipeline product portfolio comprises Duzallo (lesinurad and allopurinol), a combination product for the treatment of hyperuricemia in patients with uncontrolled gout; and other development programs. Ironwood is headquartered in Cambridge, Massachusetts, the US.

Ironwood Pharmaceuticals Inc (IRWD) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Ironwood Pharma Enters into Co-Promotion Agreement with Allergan 12
Ironwood Pharma And Protagonist Therapeutics Expand Peptide Drug Discovery Collaboration 13
AstraZeneca Enters Into Co-Development Agreement With Ironwood Pharma For Linaclotide 14
AstraZeneca Enters Into Co-Promotion Agreement With Ironwood Pharma For Nexium 16
Ironwood Pharma Enters Into Collaboration With Protagonist Therapeutics 17
Licensing Agreements 18
Ironwood Pharma Enters into Licensing Agreement with AstraZeneca 18
Ironwood Pharma Enters Into Licensing Agreement With Depomed 19
Synergy Pharma Enters Into Agreement With Ironwood Pharma For Plecanatide 20
Equity Offering 21
Ironwood Pharma Plans to Raise Funds through Public Offering of Securities 21
Ironwood Pharma Raises USD201.3 Million in Public Offering of Shares 22
Ironwood Pharma Completes Partial Exercise Of Underwriter’s Option For Public Offering Of Shares For US$146 Million 24
Ironwood Pharma Completes Public Offering Of Common Stock For US$91 Million 26
Debt Offering 28
Ironwood Pharma Raises USD150 Million in Private Placement of 8.375% Notes Due 2026 28
Ironwood Pharma Raises USD335.7 Million in Private Placement of 2.25% Notes Due 2022 29
Ironwood Pharma Completes Private Placement Of Notes Due 2024 For US$175 Million 30
Ironwood Pharmaceuticals Inc – Key Competitors 31
Ironwood Pharmaceuticals Inc – Key Employees 32
Ironwood Pharmaceuticals Inc – Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Recent Developments 34
Financial Announcements 34
Nov 02, 2017: Ironwood Pharmaceuticals Provides Third Quarter 2017 Investor Update 34
Aug 03, 2017: Ironwood Pharmaceuticals Provides Second Quarter 2017 Investor Update 39
May 08, 2017: Ironwood Pharmaceuticals Provides First Quarter 2017 Investor Update 41
Feb 21, 2017: Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2016 Investor Update 43
Nov 03, 2016: Ironwood Pharmaceuticals Provides Third Quarter 2016 Investor Update 47
Aug 04, 2016: Ironwood Pharmaceuticals Provides Second Quarter 2016 Investor Update 50
May 09, 2016: Ironwood Pharmaceuticals Provides First Quarter 2016 Investor Update 54
Feb 18, 2016: Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2015 Investor Update 57
Corporate Communications 60
Nov 28, 2017: Ironwood Pharmaceuticals Strengthens Executive Leadership Team 60
Sep 06, 2017: Ironwood Pharmaceuticals Announces Leadership Change 61
Apr 06, 2017: Ironwood Pharmaceuticals Appoints Dr. Christopher Wright as Senior Vice President of Global Development and Chief Development Officer 62
Jan 04, 2017: Ironwood Pharmaceuticals Appoints Amy Schulman to Board of Directors 63
Apr 07, 2016: Ironwood Pharmaceuticals Appoints Andrew Dreyfus to Board of Directors 64
Product News 65
03/30/2016: Ironwood Pharmaceuticals to Present Clinical Data on sGC Stimulator IW-1973 at Upcoming Scientific Conferences 65
01/15/2016: Link Between Obesity and Increased Risk of Colorectal Cancer Revealed 66
Clinical Trials 68
Feb 18, 2016: Ironwood Pharmaceuticals Progresses Vascular and Fibrotic Disease Platform with Positive Top-Line Phase Ia Data on Soluble Guanylate Cyclase Stimulator IW-1701 68
Other Significant Developments 69
Jan 08, 2017: Ironwood Pharmaceuticals Demonstrates Strong Execution on Strategy to Build Top-Performing Commercial Biotech 69
Appendix 71
Methodology 71
About GlobalData 71
Contact Us 71
Disclaimer 71

List of Tables
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 2
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Ironwood Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Ironwood Pharma Enters into Co-Promotion Agreement with Allergan 12
Ironwood Pharma And Protagonist Therapeutics Expand Peptide Drug Discovery Collaboration 13
AstraZeneca Enters Into Co-Development Agreement With Ironwood Pharma For Linaclotide 14
AstraZeneca Enters Into Co-Promotion Agreement With Ironwood Pharma For Nexium 16
Ironwood Pharma Enters Into Collaboration With Protagonist Therapeutics 17
Ironwood Pharma Enters into Licensing Agreement with AstraZeneca 18
Ironwood Pharma Enters Into Licensing Agreement With Depomed 19
Synergy Pharma Enters Into Agreement With Ironwood Pharma For Plecanatide 20
Ironwood Pharma Plans to Raise Funds through Public Offering of Securities 21
Ironwood Pharma Raises USD201.3 Million in Public Offering of Shares 22
Ironwood Pharma Completes Partial Exercise Of Underwriter's Option For Public Offering Of Shares For US$146 Million 24
Ironwood Pharma Completes Public Offering Of Common Stock For US$91 Million 26
Ironwood Pharma Raises USD150 Million in Private Placement of 8.375% Notes Due 2026 28
Ironwood Pharma Raises USD335.7 Million in Private Placement of 2.25% Notes Due 2022 29
Ironwood Pharma Completes Private Placement Of Notes Due 2024 For US$175 Million 30
Ironwood Pharmaceuticals Inc, Key Competitors 31
Ironwood Pharmaceuticals Inc, Key Employees 32
Ironwood Pharmaceuticals Inc, Subsidiaries 33

★海外企業調査レポート[Ironwood Pharmaceuticals Inc (IRWD)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Telekom Slovenije, d.d. (TLSG):企業の財務・戦略的SWOT分析
    Telekom Slovenije, d.d. (TLSG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Ibersol S.G.P.S., S.A.
    Ibersol S.G.P.S., S.A. - Strategy, SWOT and Corporate Finance Report Summary Ibersol S.G.P.S., S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Daikin Industries Ltd (6367):企業の財務・戦略的SWOT分析
    Daikin Industries Ltd (6367) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Bangkok Bank Public Co Ltd:企業のM&A・事業提携・投資動向
    Bangkok Bank Public Co Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Bangkok Bank Public Co Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • Power Assets Holdings Limited (6):電力:M&Aディール及び事業提携情報
    Summary Power Assets Holdings Limited (Power Assets) a subsidiary of CK Infrastructure Holdings Limited, is an investment holding company. The company through its subsidiaries, joint ventures, and affiliates, invests in power and utility-related businesses. The company has interests in electricity g …
  • Shandong Dongming Petrochemical Group Co Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Shandong Dongming Petrochemical Group Co Ltd (Dongming Petrochemical) is a chemicals manufacturing company that offers chemicals and petrochemicals. The group’s products include gasoline, diesel, LPG, solvent oil, liquid paraffin, polypropylene, high-grade road asphalt, petroleum refining pr …
  • VOCO GmbH:企業の戦略的SWOT分析
    VOCO GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Gaia, Inc. (GAIA):企業の財務・戦略的SWOT分析
    Gaia, Inc. (GAIA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Manitou Bf Sa:企業の戦略・SWOT・財務分析
    Manitou Bf Sa - Strategy, SWOT and Corporate Finance Report Summary Manitou Bf Sa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Angelini Group:企業の戦略的SWOT分析
    Angelini Group - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Lyft Inc (LYFT):企業の財務・戦略的SWOT分析
    Lyft Inc (LYFT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Ampcontrol Pty Ltd:企業の戦略・SWOT・財務情報
    Ampcontrol Pty Ltd - Strategy, SWOT and Corporate Finance Report Summary Ampcontrol Pty Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Fresenius SE & Co KGaA (FRE):医療機器:M&Aディール及び事業提携情報
    Summary Fresenius SE & Co KGaA (Fresenius) is a global health care group, which offers products and services for dialysis treatment. It provides various dialysis services through its own clinics and sells its products to other dialysis service providers. Its major products and services includes mach …
  • Henry Schein Inc (HSIC):企業の財務・戦略的SWOT分析
    Henry Schein Inc (HSIC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • CIMB Group Holdings Bhd:企業の戦略・SWOT・財務情報
    CIMB Group Holdings Bhd - Strategy, SWOT and Corporate Finance Report Summary CIMB Group Holdings Bhd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Primeline Energy Holdings Inc (PEH):企業の財務・戦略的SWOT分析
    Summary Primeline Energy Holdings Inc (Primeline Energy) is an upstream company that explores oil and gas. The company acquires and explores crude oil and natural gas properties across China. It owns and operates exploration and development rights in two offshore blocks in the East China Sea. Primel …
  • Sumitomo Metal Mining Co Ltd:戦略・SWOT・企業財務分析
    Sumitomo Metal Mining Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Sumitomo Metal Mining Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Sinopharm Group Co Limited:企業の戦略・SWOT・財務分析
    Sinopharm Group Co Limited - Strategy, SWOT and Corporate Finance Report Summary Sinopharm Group Co Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • NanoPass Technologies Ltd:医療機器:M&Aディール及び事業提携情報
    Summary NanoPass Technologies Ltd (NanoPass) is a medical device company that develops and commercializes intradermal delivery solutions for vaccines and drugs. The company's product include MicronJet600 needle, a single use microneedles based device for intradermal delivery. Its micronjet microneed …
  • Hana Financial Group Inc.:企業の戦略・SWOT・財務分析
    Hana Financial Group Inc. - Strategy, SWOT and Corporate Finance Report Summary Hana Financial Group Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆